FDA approves new drug developed by Boca Raton-based firm
The U.S. Food and Drug Administration has given IMVEXXY the OK, making it TherapeuticsMD's first market-approved product.
The Boca Raton-based women's health care company (Nasdaq: TXMD) developed an insert to treat vulvar and vaginal atrophy (VVA) and dyspareunia, or vaginal pain during sex caused by menopause. It will enter commercial distribution in the third quarter, as early as July.
TherapeuticsMD will market I MVEXXY as having an ultra-low dose of the estrogen steroid estadiol with the ability…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Emon Reiser Source Type: news
More News: Food and Drug Administration (FDA) | Health Management | Men | Menopause | Pain | Pharmaceuticals | Women